Rapivab Approved to Help Treat Flu
MONDAY, Dec. 22, 2014 (HealthDay News) -- Rapivab (peramivir) has been approved by the U.S. Food and Drug Administration to treat influenza.
The intravenous drug inhibits an enzyme that releases viral particles from infected cells, the FDA explained Monday in a news release. Rapivab is approved for people 18 and older who have had flu symptoms for no more than two days.
Flu affects up to 20 percent of the American population each season, hospitalizing more than 200,000 people annually, the agency noted.
Rapivab's safety and effectiveness were evaluated in a clinical study of almost 300 people with a confirmed case of the flu. Those given the newly approved drug had symptoms ease about 21 hours sooner than people who didn't take the drug, the FDA said.
Common side effects included diarrhea and serious skin reactions. And the FDA stressed that Rapivab and other antiviral drugs are not substitutes for getting the annual flu vaccine.
Rapivab is produced by BioCryst Pharmaceuticals, based in Durham, N.C.
More information
Visit the FDA to learn more.
Related Articles
Search Allergy Articles
Could Inhaling a Statin Help Ease Asthma, COPD?
What Is Chronic Sinusitis, and How Is it Treated?
Seniors, Here Are the Meds That Can Harm Your Driving Skills
Dangerous Allergies? An Expert Gives Tips to Protect Yourself
COVID Does Not Spur Asthma in Kids, Study Finds
Planning Safe Summer Camp Fun for Kids With Allergies & Asthma
Canadian Wildfire Smoke Caused Spikes in Asthma-Related ER Visits Across the U.S.
Biden Administration to Tighten Air Pollution Standards
Asthma Inhaler Switch in 2024 Could Leave Some Patients Scrambling